Copyright © Inderes 2011 - present. All rights reserved.

Careium

20.35 SEK

Less than 1K followers

CARE

First North Stockholm

Hardware Manufacturer

Technology

-1.69 %
-16.60 %
-14.50 %
-24.35 %
-14.14 %
-40.50 %
+44.33 %
-
-36.60 %

Careium offers security solutions such as security alarms, smart sensors and digital visits, with its own alarm center that is staffed 24/7. The product offering includes security alarms, sensors and accessories such as cameras and electronic locks. The company targets private individuals, municipalities and care organizations, and is active in several countries in Europe. The company is headquartered in Malmö, Sweden.

Read more
Market cap
495.04M SEK
Turnover
-
Revenue
854.1M
EBIT %
5.76 %
P/E
15.3
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
23.4
2026

General meeting '26

23.4
2026

Interim report Q1'26

10.7
2026

Interim report Q2'26

ShowingAll content types
Third party research

Careium: Bittersweet outlook on 2026 - ABG

* Margin pressure to remain in H1'26e * We cut our '26-'27 EBIT estimates by 15% and 9% * Share is trading at 9x-7x '26e-'27e EV/EBIT EBIT materially lower than anticipated Careium delivered solid sales in Q4, with organic growth of 6.3% despite tough...

Careium
Third party research

Careium: Margin pressure to remain in H1'26 - ABG

* Q4 sales 4% above our ests. at SEK 231m, for 6% org. growth * Adj. EBIT SEK 8m vs. ABGSCe 22m * Trading at 8x-7x '26e-'27e EV/EBITA adj. Solid sales but material opex growth Q4 came in above expectations on sales, but materially below on EBIT. Careium...

Careium

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Careium: At the end of a rough stretch - ABG

* Q4e: 4% organic sales growth, 11% adj. EBITA margin * We cut estimates on the downgraded outlook * Trading at 8x '26e adj. EV/EBITA The final quarter of a tough year We expect Q4 sales and adj. EBITA of SEK 227m and SEK 24m, respectively, corresponding...

Careium
Third party research

Careium: Downgrades '25e outlook - ABG

* Careium states that it will not meet FY'25 outlook...* ... Implying FY'25 sales growth of -2%* Mechanical effect on '25 estimates imply 4% cut on EBITCareium will not meet its '25e outlookCareium has downgraded its full-year outlook, which was previously...

Careium
Third party research

Careium: Careful steps forward - ABG

* Q3: Softer than expected, but back to growth* We cut our sales and adj. EBITA estimates* Share is trading at 11x-7x '25e-'26e EV/EBITA adj.Softer than expectedCareium delivered solid sales in Q3, with organic growth of 9.4% compared to -8% in Q3'24...

Careium
Third party research

Careium: Back to growth, but soft on earnings - ABG

* Q3 sales 3% below our ests. at SEK 214m, for 9.4% org. growth* Adj. EBIT SEK 19m vs. ABGSCe 22m* Trading at 9x-7x '25e-'26e EV/EBITA adj.Solid growth, EBIT weighed down by financial leasesCareium delivered sales of SEK 214m (-3% vs ABGSCe 221m), correspondin...

Careium
Third party research

Careium: Turning a corner - ABG

* Q3e: 11% organic sales growth, 10% adj. EBITA margin* We lower estimates on continued lack of upfront revenue* Trading at 9x-6x '25e-'27e adj. EV/EBITAH2 could deliver a recoveryWe expect Q3 sales and adj. EBITA of SEK 221m and SEK 25m, respectively...

Careium
Third party research

Careium: Continued headwinds in Sweden - ABG

- Q2 sales 8% below our ests. at SEK 202m, for -9% org. growth - EBIT SEK 10m vs. ABGSCe 18m - Trading at 9x '25e EV/EBITA adj. Q2: A soft quarter, partly on accounting effects Careium delivered sales of SEK 202m (-8% vs ABGSCe 220m), corresponding to...

Careium
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.